Cycle Pharmaceuticals Launches New Informative Online Meeting Series For Patients With Tyrosinemia Type 1 In The Us
Boston (MA), USA, April 13, 2020 – Cycle Pharmaceuticals (“Cycle”) is pleased to announce the launch of a new online meeting series for patients and their families with Hereditary Tyrosinemia Type 1 (HT-1) in the US. The meeting series is led by Renata Tate, RD, MSN, Head of Patient Liaison Services at Cycle.
The monthly meeting series called “Tyrosinemia Connections: A Live Community Event” will feature invited speakers presenting informative subjects, as well as low protein recipes, news from patient advocacy groups and Q&A sessions. The first event will take place on April 28th at 12-1 pm (EST) and again at 7-8 pm (EST). Patients and families can register by submitting an e-mail to [email protected].
“The newly created Patient Liaison Services at Cycle is proud to present this online initiative that aims at bringing the community together especially in the current times of travel and meeting restrictions. Being HT-1 an ultra-rare condition, patients and their families often lack reliable sources of information and news about their condition. We would like to bridge that gap by providing a space for this community to grow, get together and learn” said Renata Tate, Head of Patient Liaison Services, Cycle Pharmaceuticals.
HT-1 is an ultra-rare genetic disease that can cause hepatic, renal and neurological complications. In most cases, if left untreated, the disease is fatal. It is estimated that HT-1 affects less than 200 patients in the United States.
“This program is aligned with Cycle’s patient-centricity values. Every orphan drug we improve and every patient program we create, is always designed with patients at heart. This new initiative is open to every HT-1 patient in the US and we are extremely happy to provide this support at these unprecedented times” said Antonio Benedetti, CEO, Cycle Pharmaceuticals.
About Cycle Pharmaceuticals Limited
Cycle is a pioneering pharmaceutical company, reimagining how drugs can benefit patients to make their lives easier and improve their quality of life at every stage. Specifically, Cycle focuses on improving orphan drugs, which treat under-served rare disease patient community.
Cycle is committed to changing the way that HT-1 is treated and managed around the world. Cycle has worked for more than four years with physicians and patient groups to reduce the impact that HT-1 treatment has on patients’ lives.
With Headquarters in Cambridge, U.K. and offices in Boston, Mass. (USA), Cycle has developed unique partnerships with renowned universities around the world. For further information, please visit www.cyclepharma.com
FOR FURTHER INFORMATION AND INTERVIEWS PLEASE CONTACT
Paula Bekinschtein, Head of Global Marketing
Cycle Pharmaceuticals
Email: [email protected]
Company’s website: www.cyclepharma.com